Latest market price
3.87
-0.13-3.25%
OverviewShort InterestFilings
SIONQT8Sionna Therapeutics, Inc.·NASDAQ
3.87-3.25%
TA
Loading chart...
Signal & projected range
Falling wedge — reversalHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-2.18Insider Own—Shs Outstand45.15MPerf Week7.50%
Market Cap174.73MForward P/E—EPS next Y-2.29Insider Trans-15.63%Shs Float23.56MPerf Month-24.12%
Enterprise Value119.48MPEG—EPS next Q-0.64Short Float15.61%Perf Quarter-92.14%
Income-97.00MP/S—EPS this Y—Short Ratio1.64Perf Half Y-90.11%
Sales0.00P/B0.66EPS next Y—ROA-34.38%Short Interest3.68MPerf YTD-90.59%
Book/sh5.89P/C0.83EPS next 5Y—ROE-32.94%52W High54.97 -92.96%Perf Year-89.69%
Cash/sh4.67P/FCF—EPS past 3/5Y—ROIC-39.98%52W Low3.55 9.01%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility6.82% 7.23%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.43Perf 10Y—
Dividend Ex-Date—Quick Ratio20.05Sales Y/Y TTM—Profit Margin0.00%RSI (14)31.21Recom2.75
Dividend Gr. 3/5Y—Current Ratio20.05EPS Q/Q-60.98%SMA20-8.13%Beta1.38Target Price27.40
Payout0.00%Debt/Eq0.03Sales Q/Q—SMA50-28.94%Rel Volume0.23Prev Close4.00
Employees59LT Debt/Eq0.03EarningsNov 04SMA200-87.15%Avg Volume2.33MPrice3.87
IPO DateFeb 07, 2025Option/ShortNo / YesEPS/Sales Surpr.-1.54% —Net Debt/EBITDA—Volume534,344Change-3.25%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26ReiteratedWedbushNeutral$5.00 → $6.00
Aug-11-26DowngradeWedbushOutperform → Neutral$5.00
Aug-11-26DowngradeGuggenheimBuy → Neutral$60
Aug-10-26ReiteratedRBC CapitalUnderperform$24 → $5.00
Aug-10-26ReiteratedStifel Nicolaus$55 → $7.00
Aug-10-26DowngradeBTIGBuy → Neutral
Aug-07-26ReiteratedGuggenheimBuy$50 → $60
Aug-06-26ReiteratedRaymond James$53 → $59
May-20-26DowngradeFreedom BrokerBuy → Hold
May-18-26ReiteratedStifel Nicolaus$44 → $55
Latest News· Times ET
Oct-12-26
Oct-12-2610:35AM
Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerzacks.com
Oct-08-26
Oct-08-2604:30PM
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conferenceglobenewswire.com
04:29AM
Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33 According to Brokeragesdefenseworld.net
Oct-06-26
Oct-06-2606:37PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONglobenewswire.com
Oct-01-26
Oct-01-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONprnewswire.com
Sep-29-26
Sep-29-2605:22PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONglobenewswire.com
Sep-24-26
Sep-24-2605:34PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONprnewswire.com
Sep-21-26
Sep-21-2605:06PM
These beaten-down stocks could bounce back in January, if history is any guidemarketwatch.com
Sep-17-26
Sep-17-2605:21PM
Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?Yahoo
10:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONprnewswire.com
Sep-16-26
Sep-16-2612:31PM
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Downzacks.com
01:29AM
Brokerages Set Sionna Therapeutics, Inc. (NASDAQ:SION) Price Target at $42.22defenseworld.net
Sep-15-26
Sep-15-2605:08PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONglobenewswire.com
06:31AM
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcriptseekingalpha.com
06:15AM
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program - SlideshowSeekingAlpha
Company

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
0000—
Cost of Goods Sold Incl. D&A0110—
Gross Profit0-1-10—
Selling, General and Administrative Excl. Other38291310—
Research and Development72605741—
Other Operating Expense-2-10-1—
Operating Income-110-89-71-50—
Interest Expense
0000—
Unusual Expense
—————
Non-Operating Income (Expense)131493—
Net Income Before Taxes-97-75-62-47—
Income Taxes
0000—
Consolidated Net Income-97-75-62-47—
Net Income From Continuing Operations-97-75-62-47—
Net Income-97-75-62-47—
EPS (Recurring)-2.18-1.88-1.40-1.07—
EPS (Basic, Before Extraordinaries)-2.18-1.88-1.40-1.07—
EPS (Diluted)-2.18-1.88-1.40-1.07—
EBITDA-94-75-61-47—
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio
—————
Gross Margin
—————
Operating Margin
—————
Net Margin
—————
Shares Outstanding45404444—
Market Capitalization1741,646———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$58.16$42.74$27.32$11.90$-3.52● Close Price0.00M12.71M25.42M38.13M50.83MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
RA CAPITAL MANAGEMENT, L.P.Director, 10% OwnerSep 17 '26Sale6.333,448,81121,835,0183,448,812Sep 21
Thompson Peter A.DirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09
ORBIMED ADVISORS LLCDirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Option Exercise6.1110,25062,62810,250Jul 07
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Sale43.6010,250446,8620Jul 07
Thompson Peter A.DirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02
ORBIMED ADVISORS LLCDirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02
Thompson Peter A.DirectorMay 27 '26Sale44.491014,4932,671,721May 29
ORBIMED ADVISORS LLCDirectorMay 27 '26Sale44.491014,4932,671,721May 29
ORBIMED ADVISORS LLCDirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11
Thompson Peter A.DirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11
ORBIMED ADVISORS LLCDirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11
Thompson Peter A.DirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11
ORBIMED ADVISORS LLCDirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11
Thompson Peter A.DirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.